In a study focused on the use of magic mushrooms in Canada, nearly 80% of participants expressed their opinion that psilocybin should be accessible as a medical treatment for distressed patients. In the same study, approximately two-thirds of the Canadian participants concurred that psilocybin should be legally available for those who need it.
Moreover, a substantial 84.8 percent of participants are of the view that the public health system should cover the costs of such treatments. A significant number of Canadians see psilocybin as a practical option, particularly for the treatment of end-of-life distress.
[toc]
Key Findings:
- Residents of Québec, Ontario, Alberta, and British Columbia perceive psilocybin as a legitimate medical option for managing end-of-life existential distress.
- Magic mushrooms are deemed safe for the treatment of existential distress.
- Participants in two double-blind studies reported immediate and long-lasting benefits, with effects enduring six months or more.
Understanding Existential Distress
Existential distress, akin to existential suffering, spiritual distress, and demoralization, arises when individuals grapple with their mortality. Patients may grapple with feelings of helplessness, isolation, anxiety, and a sense of lost meaning and purpose. This type of distress particularly impacts patients with life-threatening illnesses, potentially leading to thoughts of hastening death or contemplating suicide.
Often, individuals confronting terminal illnesses or significant life changes are those who experience this kind of distress. It severely impacts their mental health and overall life quality.
Existential therapy aims to confront issues such as anxiety, depression, grief, loneliness, apathy, despair, identity confusion, and feelings of purposelessness and existential fear. It typically involves multiple sessions and may not be beneficial for everyone.
The uncertainty about the effectiveness of this kind of therapy is a major factor driving many individuals to seek alternative treatments.
Health Canada’s Perspective on Psilocybin for Treatment Purposes
Preliminary clinical trials over the last two decades have highlighted the potential advantages of psychedelic substances in addressing complex mental disorders. Notably, Psilocybin has demonstrated a quick and long-term relief of existential distress for patients approaching the end of life.
Recognizing the potential efficacy of these proposed hallucinogenic mushrooms, especially when conventional treatments are inadequate, Health Canada revised the Special Access Program in 2022. This revision permits healthcare practitioners to apply for controlled substances on behalf of their patients.
Canadian Advocacy for Psilocybin Accessibility
An article in the Palliative Care Journal explores societal views on psilocybin-assisted therapy for end-of-life care. The data from the study includes:
| Method | Survey of 2,800 Canadians from Québec, Ontario, Alberta, and British Columbia, 19% of whom had previously used psilocybin (15% in Québec, 26% in British Columbia). |
| Results | 79.3% acknowledge psilocybin-assisted therapy as a viable medical option for treating end-of-life existential distress. 63.3% support integrating psilocybin into medical treatment. 84.8% endorse the public health system’s provision of this therapy. 44.2% believe healthcare professionals should administer the substance without Health Canada’s supervision. |
The above findings align with surveys conducted in Canada, England, and Australia. The researchers stressed that their study is distinctive as it focuses on the use of psychoactive substances for managing existential distress in end-of-life situations.
Why Canadians Support Psilocybin Usage
An increasing number of Canadians support psilocybin for treatment, largely influenced by research findings from esteemed institutions. Another driving factor is the perceived safety of psilocybin mushrooms in mitigating existential distress. There have been no reports of severe adverse health effects, including multi-organ failure, across various studies.
| Research | Method | Results |
| Johns Hopkins Study | 51 patients received a high dose of psilocybin and a low dose as an active placebo control | Immediate and prolonged The effectiveness of this therapy primarily stems from mystical experiences that induce a sense of unity and deep emotional understanding, which can yield benefits for up to six months or even longer. |
| New York University Study | A total of 29 patients were randomly selected to either receive psilocybin or the active placebo, niacin. | The results of this trial echoed those of the Johns Hopkins study, with participants who were administered psilocybin reporting psychological relief and a renewed outlook on life and mortality. |
| BMC Palliative Care Study | Nineteen participants were interviewed, including 7 doctors, 4 practicing nurses, 4 chaplains, 3 social workers, and 1 psychologist. The objective of the study was to comprehend how palliative care professionals perceive existential distress and their opinions on psychedelic therapy as a treatment method. | Palliative care professionals suggested that psychedelic-assisted therapy (PAT) could potentially alleviate existential distress. |
Patient Experiences
Besides scientific research, numerous patient stories also support the efficacy of psilocybin. These accounts highlight its potential to improve mental health and overall quality of life.
Mio Yokoi’s Experience
Mio Yokoi, a terminal stage 4 pancreatic cancer patient, shares her enlightening journey during her psychedelic-assisted therapy. She imagines herself on a raft, surrounded by scenic nature and accompanied by whimsical creatures. This vision evokes in her a profound sense of unity with the universe and offers her immense peace and validation.
Despite receiving conventional mental health support, Yokoi continued to grapple with severe anxiety and distress following her diagnosis. Psilocybin therapy enabled her to reconnect with her body and provided a tangible sense of love and support, significantly improving her emotional and mental wellbeing.
The Journey of Chrissy
Chrissy, a woman in her 50s, was diagnosed with stage 4 breast cancer that had metastasized to her lungs. At the time of the study, she was working full-time as an administrative supervisor in healthcare and identified as an atheist. She was diagnosed with Generalized Anxiety Disorder during her initial screening.
Chrissy reported significant reductions in her anxiety, depression, fear of death, hopelessness, and demoralization levels. When asked if her religious or spiritual beliefs had changed since her therapy session, she replied that her experiences had brought a new depth of meaning and authenticity to her beliefs.
Brenda’s Journey
Throughout her therapy sessions, Brenda experienced the phenomenon of dying twice. Following these sessions, she no longer feared death, but saw it as a beautiful part of the cycle of life. She credited the study for sparking her healing process from past childhood trauma. Her progress data reflected this remarkable transformation.
She exhibited decreased anxiety and fear of death, along with an increase in spiritual awareness.
Availability of Psilocybin Mushroom Products in Canada
At present, access to psilocybin capsules and other related products for managing existential distress or other mental health problems might be limited. However, reliable online dispensaries can be a valuable resource for obtaining these products when necessary.
| Property | Brazilian Psilocybe Cubensis | Cambodian Psilocybe Cubensis | Melmac Psilocybe Cubensis |
| Origin | Native to Brazil and some neighboring South American countries. | Discovered in Cambodia, around the Angkor Wat Temple. | Associated with Penis Envy mushrooms, which became popular in the 1970s. |
| Strength | Medium potency; suitable for first-time users. | Moderate strength; perfect for beginners. | Highly potent; advisable for those with a moderate to high level of experience. |
| Effects | Produces a mental rush, slight disorientation, enhanced color perception, euphoria, spiritual experiences, increased creativity, and improved concentration. | Induces an energizing, long-lasting high, minor visual changes, increased creativity, euphoria, a gentle physical high, fractal visuals, and feelings of happiness. | Leads to profound shamanic experiences, vision quests, intense mystical experiences, enhanced creativity, focus, social consciousness, and mood improvement. |
Ease End-of-life Discomfort with Psilocybin Products
Existential or end-of-life distress can place a significant emotional burden on individuals nearing the end of their lives. Traditional treatments can often be ineffective, leading to an increase in support within Canada for the integration of magic mushrooms into public healthcare. This growing public interest could We urge regulatory authorities to evaluate the potential of magic mushrooms as a feasible treatment option. Obtain your psychedelics and shroom delivery from Fungalfriend Canada.
Frequently Asked Questions
What can patients expect from Psilocybin-Assisted Therapy?
The experience of patients with Psychedelic-assisted therapy (PAT) can significantly differ, and meticulous preparation and strict adherence to certain procedures are crucial for a positive outcome. Patients need comprehensive screening and mental readiness before taking the substance.
- Preparation before the Session: A thorough assessment of patients takes place. The therapist discusses the patient’s goals and expectations to set intentions for the session. The therapist also conveys to the patient the potential effects of the process and what they can expect during the session.
- The Session: A controlled dose of the substance is given to patients in a quiet, comfortable environment to foster relaxation and self-reflection. The therapist offers continuous support and guidance throughout this process.
- Post-Session Integration Therapy: This therapy helps patients comprehend and assimilate their experiences. Further sessions provide ongoing support and counselling to reinforce the insights and transformations gained during therapy.
How does psilocybin affect the brains of patients in distress?
Psilocybin interacts with the brain by binding to serotonin receptors, principally the 5-HT2A receptor. This interaction can lead to alterations in perception, mood, and cognition, resulting in profound changes in consciousness, emotional breakthroughs, and new insights.
Is psilocybin therapy available to everyone?
Psilocybin therapy is not appropriate for everyone. Patients with certain mental health conditions or existential distress are thoroughly screened to exclude those with a history of psychosis.
Relevant Articles:
